Brief: Zealand Pharma Says Study In Glucagon/GLP-1 Dual Agonist Survodutide Met Primary Endpoints

Zealand Pharma A/S

28/04/2026 07:11

April 28 (Reuters) - Zealand Pharma A/S ZELA.CO:

ANNOUNCES BOEHRINGER INGELHEIM'S NOVEL GLUCAGON/GLP-1 DUAL AGONIST SURVODUTIDE ACHIEVED SIGNIFICANT WEIGHT LOSS OF 16.6% DELIVERING MEANINGFUL METABOLIC IMPROVEMENT IN PEOPLE WITH OBESITY OR OVERWEIGHT IN PHASE 3 TRIAL

TRIAL MET BOTH WEIGHT LOSS PRIMARY ENDPOINTS

TRIAL MET KEY SECONDARY ENDPOINT EVALUATING WAIST CIRCUMFERENCE, A PREDICTOR OF CARDIOMETABOLIC RISK

Source text: ID:nGNE1YlNR6

Further company coverage: ZELA.CO

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))